Ricercatori tedeschi: possibili rischi cardiovascolari da vaccino anti H1N1 posted on 19-11-2009
Un recente articolo di ricercatori della univervsità di Mainz lancia l'allarme di possibili eventi avversi cardiovascolari da vaccino anti H1N1 con adiuvante (come quello presente in Italia).
Riporto parte dell' abstract di un recente articolo di ricercatori dell' Univervsità di Mainz (Germania).  Il grassetto è del curatore
"We draw attention to unappreciated hazards of using adjuvanted vaccine in Europe. Evidence from animal experiments in conjunction with clinical epidemiological data indicates that, quite irrespective of cause, stimulation of the immune system may accelerate atherogenesis. Application of adjuvanted flu vaccines to individuals at risk may therefore aggravate the course of underlying atherosclerotic vessel disease with all the clinical consequences."
Per una migliore comprensione dell'articolo che solleva importanti domande, riporto alcuni passi significativi dell' articolo completo
Dottor Andrea Valeri, coordinatore SIMO influenza working group mail: firstname.lastname@example.org
...MF59, a squalene oil-in-water emulsion with yet poorly delineated mechanism of action, appears to target monocytes, macrophages and dendritic cells via mechanisms distinct from those mediated from danger signals. MF59 induces macrophage recruitment to the injection site and appears to promote uptake of antigen by macrophages and dendritic cells.....
This is particularly relevant in the present context because it highlights the fact that macrophage stimulation accelerates atherogenesis in the absence of any infection
...These few examples should suffice to transmit that if, at any stage, vaccination drives macrophages into their inflammatory state, the effects on atherosclerosis will hardly be unpredictable and acute clinical events could be precipitated. Causes might be the adjuvant or another ingredient, a combination of both, or any other inflammatory events provoked by intramuscular injection of the vaccine.
Against this background, the discomforting question arises whether any clinical data exist that would relieve us of these concerns. The simple answer is no. Although millions of individuals have been vaccinated with the adjuvanted flu vaccine, data relating to any of the previous questions have not been systematically acquired. Trials conducted with H1N1 vaccines also do not and cannot address these questions. Such trials would have to be conducted in individuals with identified risk factors, and observations would have to be made over extended periods of time. The latter also holds for healthy young individuals who are to repeatedly receive adjuvanted vaccines over years or decades. That unknown dangers may also be lurking here should be self-evident. To top matters, the GSK flu vaccine with its novel combination of adjuvant and additives has not ever been applied to a large number of recipients. The adjuvant included in the GSK vaccine is AS03 in the same or similar formulation previously employed in the adjuvanted H5N1 influenza vaccine . The safety of that vaccine was assessed in 400 volunteers...
Bhakdi S, Lackner K, Doerr HW. Possible hidden hazards of mass vaccination against new influenza A/H1N1: have the cardiovascular risks been adequately weighed? Med Microbiol Immunol. 2009 Oct 23
|Trova un omeopata accreditato vicino a te|
|Registro Italiano dei
e Veterinari Omeopati Accreditati
| Sei un medico o un veterinario e pratichi la Medicina Omeopatica?
Chiedi l'iscrizione al Registro Italiano dei Medici e Veterinari Omeopati accreditati.
|[10.07.2019] Homeopathy and depression - Positive evidence collection
Omeopatia e depressione - Raccolta bibliografica delle evidenze positive
|[08.06.2019] Evidence Based Yoga: osteoporosi e disturbi cognitivi - Teis (Bz)||[11.05.2019] L'efficacia dell'Omeopatia: evidenze e sviluppi||[03.12.2018] Appello per uno STOP all'ingiustificato ed antiscientifico attacco contro i medici omeopati|